

# Lung Cancer Treatment **controversies**



2026

06-07 NOVEMBER • PORTO



Preliminary Program



# 2026

06-07 NOVEMBER · PORTO




## Organizing Committee / Scientific Coordinators

António Araújo  
Delvys Rodriguez-Abreu  
Stephen Liu  
Luiz Paz-Ares

## Scientific Panel

Alfredo Addeo (1)  
Alvaro Quintanal-Villalonga (2)  
Andrea Ardizzoni (3)  
António Araújo (4)  
Benjamin Besse (5)  
Cecilia Pompili (6)  
Christian Rolfo (7)  
Delvys Rodriguez-Abreu (8)  
Enriqueta Felip (9)  
Fiona Blackhall (10)  
Joachim Aerts (11)  
Jessica Lin (12)  
Jordi Remon (13)  
Lizza Hendriks (14)  
Luiz Paz-Ares (15)  
Martin Reck (16)  
Rosario Garcia Campelo (17)  
Stephen Liu (18)  
Suresh Senan (19)



## General Information

**Venue:**  
School of Medicine and  
Biomedical Sciences – ICBAS,  
University of Porto  
Rua de Jorge de Viterbo Ferreira, 228,  
4050-313 Porto

**Technical Secretary:**  
Skyros  
Congressos, Lda

**Language:**  
English

## Format

Short lectures, pro-con debates, to draw conclusions from the debate and to vote among all the audience.

## Audience

Thoracic oncologists, surgeons, radiation oncologists, translational researchers.



# Day 1

**Friday, 6 November**

08:15

› **Registration opening**

08:45–09:00

› **Welcome & Objectives**

## Session 1

09:00–13:00

### Early Stages: Are We Over or Under-Treating?

*Chairs: Delvys Rodriguez-Abreu & Christian Rolfó*

*Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)*

■ Perioperative vs neo-adjuvant IO.

*Speakers: Lizza Hendriks vs Alfredo Addeo*

■ Are we ready for targeted therapy in resected oncogene-driven NSCLC?

*Speakers: Jessica Lin vs Rosario Garcia Campelo*

10:45–11:15 › Coffee Break

■ Should MRD guide adjuvant therapy in 2026?

*Speaker: Christian Rolfó*

■ In multiple station N2, bulky N2 or T4 – Neoadjuvant pre-surgery or chemoradiation and IO?

*Speakers: Cecilia Pompili vs Suresh Senan*

13:00–14:00 › Lunch

## Session 2

14:00–18:00

### First-line Treatment for advanced NSCLC: what is the size?

*Chairs: Stephen Liu & Jessica Lin*

*Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)*

■ In PD-L1  $\geq$  50% IO alone vs chemo-IO or IO combinations.

*Speakers: Stephen Liu vs Enriqueta Felip*

■ Sequencing vs combinations in oncogene-driven disease.

*Speakers: Delvys Rodriguez-Abreu vs Jessica Lin*

15:45–16:15 › Coffee Break

■ What is the best duration of the IO therapy? Two years vs until disease progression.

*Speakers: Benjamin Besse vs Joachim Aerts*

■ The value of new strategies (like ADCs or bispecific antibodies) vs (and) the need for new biomarkers.

*Speaker: Jordi Remon*

**19:30 › Networking Dinner**

# Day 2

**Saturday, 7 November**

## Session 3

09:00–13:00

### mSCLC: is this the future?

*Chairs: António Araújo & Luiz Paz-Ares*

*Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)*

■ Molecular subtypes and other biomarkers: ready for clinical use?

*Speaker: Alvaro Quintanal-Villalonga*

■ Maintenance with PD-L1/PD-1 inhibitors or Lurbinectedin+Atezolizumab?

*Speakers: Andrea Ardizzoni vs Martin Reck*

10:45–11:15 › Coffee Break

■ T-Cells Engager – some patients in some centers or most patients in most centers?

*Speakers: Fiona Blackhall vs Luiz Paz-Ares*

■ After chemo-immunotherapy progression: should we move directly to T-cell engagers or still sequence conventional therapies?

*Speakers: Benjamin Besse vs Stephen Liu*

**13:00–13:30 › Closing Session**

■ Take-home messages and consensus gaps

■ Proposal for post-meeting position paper